Asp J, Sangiorgi L, Inerot S E, Lindahl A, Molendini L, Benassi M S, Picci P
Research Center for Endocrinology and Metabolism, Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Int J Cancer. 2000 Mar 15;85(6):782-6. doi: 10.1002/(sici)1097-0215(20000315)85:6<782::aid-ijc7>3.0.co;2-o.
The role of two important tumour suppressor genes, p16 and p53, was evaluated in cartilaginous tumour tissues. Genomic DNA from 22 chondrosarcomas, 5 benign chondroid tumours, 1 sample of reactive proliferative cartilage and 2 samples of normal cartilage were analysed using polymerase chain reaction, single strand conformational polymorphism, DNA sequencing and methylation-specific polymerase chain reaction. The p16 gene was found to be partly methylated in 5 high-grade chondrosarcomas and homozygously deleted in 1 chondrosarcoma. Moreover, a polymorphism was detected in 3 malignant tumours, but not in benign tumours or normal cartilage. Analysis of the p53 gene revealed an unchanged structure in all samples. These findings show a role for p16, but not p53, in chondrosarcoma.
在软骨肿瘤组织中评估了两个重要的肿瘤抑制基因p16和p53的作用。使用聚合酶链反应、单链构象多态性、DNA测序和甲基化特异性聚合酶链反应，对22例软骨肉瘤、5例良性软骨样肿瘤、1例反应性增生性软骨样本和2例正常软骨样本的基因组DNA进行了分析。发现p16基因在5例高级别软骨肉瘤中部分甲基化，在1例软骨肉瘤中纯合缺失。此外，在3例恶性肿瘤中检测到多态性，但在良性肿瘤或正常软骨中未检测到。对p53基因的分析显示所有样本的结构均未改变。这些发现表明p16在软骨肉瘤中发挥作用，而p53则不然。
